APLS Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of 43.91%. Apellis Pharmaceuticals's return on equity of -96.34% beat Arvinas's return on equity of -7.72%.

Apellis Pharmaceuticals has a consensus price target of $36.62, signalling upside risk potential of 109.97%. On the other hand Arvinas has an analysts' consensus of $19.42 which suggests that it could grow by 198.26%. Given that Arvinas has higher upside potential than Apellis Pharmaceuticals, analysts believe Arvinas is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are smaller than Arvinas quarterly revenues of $188.8M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Arvinas's net income of $82.9M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.80x versus 1.10x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -1366.49%. Apellis Pharmaceuticals's return on equity of -96.34% beat Recursion Pharmaceuticals's return on equity of -82.61%.

Apellis Pharmaceuticals has a consensus price target of $36.62, signalling upside risk potential of 109.97%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.43 which suggests that it could grow by 82.07%. Given that Apellis Pharmaceuticals has higher upside potential than Recursion Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Recursion Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Recursion Pharmaceuticals quarterly revenues of $14.8M. Apellis Pharmaceuticals's net income of -$92.2M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.80x versus 21.56x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -151.35%. Apellis Pharmaceuticals's return on equity of -96.34% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

Apellis Pharmaceuticals has a consensus price target of $36.62, signalling upside risk potential of 109.97%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $82.08 which suggests that it could grow by 31.63%. Given that Apellis Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.362, suggesting its more volatile than the S&P 500 by 136.233%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.80x versus 28.12x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Y-mAbs Therapeutics has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -24.86%. Apellis Pharmaceuticals's return on equity of -96.34% beat Y-mAbs Therapeutics's return on equity of -30.14%.

Apellis Pharmaceuticals has a consensus price target of $36.62, signalling upside risk potential of 109.97%. On the other hand Y-mAbs Therapeutics has an analysts' consensus of $15.50 which suggests that it could grow by 258.8%. Given that Y-mAbs Therapeutics has higher upside potential than Apellis Pharmaceuticals, analysts believe Y-mAbs Therapeutics is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Y-mAbs Therapeutics has a beta of 0.531, suggesting its less volatile than the S&P 500 by 46.863%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Y-mAbs Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Y-mAbs Therapeutics pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Y-mAbs Therapeutics quarterly revenues of $20.9M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Y-mAbs Therapeutics's net income of -$5.2M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Y-mAbs Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.80x versus 2.18x for Y-mAbs Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.